These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against ...

Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh Lipton and Julie Hyman to discuss the impact of tariffs on the biotech sector.

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative direction, according to Goldman analyst Salveen Richter. Consequently ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Yigal Nochomovitz; Analyst; Citigroup Inc. Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

Goldman Sachs US Biotechnology Analyst Salveen Richter explains on "Bloomberg Markets." Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for ...